Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma

References

• HideshimaTMitsiadesCTononGRichardsonPGAndersonKCUnderstanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targetsNat Rev Cancer20077858559817646864
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarVKyleRAMultiple myelomaNat Rev Dis Primers201731704628726797
   PubMed Web of Science ®Google Scholar
• BianchiGRichardsonPGAndersonKCPromising therapies in multiple myelomaBlood2015126330031026031917
   PubMed Web of Science ®Google Scholar
• FairfieldHFalankCAveryLReaganMRMultiple myeloma in the marrow: pathogenesis and treatmentsAnn N Y Acad Sci201613641325127002787
   PubMed Web of Science ®Google Scholar
• de La PuentePAzabAKNanoparticle delivery systems, general approaches, and their implementation in multiple myelomaEur J Haematol201798652954128208215
   PubMed Web of Science ®Google Scholar
• VisaniGLoscoccoFIsidoriANanomedicine strategies for hematological malignancies: what is next?Nanomedicine20149152415242825413858
   PubMed Web of Science ®Google Scholar
• LamichhaneNUdayakumarTSD’SouzaWDLiposomes: clinical applications and potential for image-guided drug deliveryMolecules2018232E28829385755
   PubMed Web of Science ®Google Scholar
• Martínez-JotharLDoulkeridouSSchiffelersRMInsights into maleimidethiol conjugation chemistry: conditions for efficient surface functionalization of nanoparticles for receptor targetingJ Control Release201828210110929526739
   PubMed Web of Science ®Google Scholar
• KoningGASchiffelersRMWaubenMHTargeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritisArthritis Rheum20065441198120816575845
   PubMed Web of Science ®Google Scholar
• MitsiadesCSMitsiadesNSMunshiNCRichardsonPGAndersonKCThe role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactionsEur J Cancer200642111564157316765041
   PubMed Web of Science ®Google Scholar
• MichigamiTShimizuNWilliamsPJCell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4) beta(1)-integrin enhances production of osteoclast-stimulating activityBlood20009651953196010961900
   PubMed Web of Science ®Google Scholar
• SchülerJEwerthDWaldschmidtJWäschREngelhardtMPreclinical models of multiple myeloma: a critical appraisalExpert Opin Biol Ther201313Suppl 1S111S12323742200
   PubMedGoogle Scholar
• LwinSTEdwardsCMSilbermannRPreclinical animal models of multiple myelomaBonekey Rep2016577226909147
   PubMedGoogle Scholar
• GroenRWNoortWARaymakersRAReconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myelomaBlood20121203e9e1622653974
   PubMed Web of Science ®Google Scholar
• KirshnerJThulienKJMartinLDA unique three-dimensional model for evaluating the impact of therapy on multiple myelomaBlood200811272935294518535198
   PubMed Web of Science ®Google Scholar
• FerrariniMSteimbergNPonzoniMCorrection: ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of multiple myeloma biology and response to therapyPLoS One2013810
   Google Scholar
• ReaganMRMishimaYGlaveySVInvestigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche modelBlood2014124223250325925205118
   PubMed Web of Science ®Google Scholar
• de La PuentePMuzBGilsonRC3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myelomaBiomaterials201573708426402156
   PubMed Web of Science ®Google Scholar
• JakubikovaJCholujovaDHideshimaTA novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applicationsOncotarget2016747773267734127764795
   PubMedGoogle Scholar
• EetezadiSDe SouzaRVythilingamMLessa CataldiRAllenCEffects of doxorubicin delivery systems and mild hyperthermia on tissue penetration in 3D cell culture models of ovarian cancer residual diseaseMol Pharm201512113973398526394060
   PubMedGoogle Scholar
• PattniBSNagelliSGAryasomayajulaBTargeting of micelles and liposomes loaded with the pro-apoptotic drug, NCL-240, into NCI/ADR-RES cells in a 3D spheroid modelPharm Res201633102540255127351426
   PubMed Web of Science ®Google Scholar
• López-DávilaVMagdeldinTWelchHDwekMVUchegbuILoizidouMEfficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro modelNanomedicine201611433134426786002
   PubMed Web of Science ®Google Scholar
• BrahamMVJMinnemaMCAartsTCellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche modelOncoimmunology201876e143446529872571
   PubMed Web of Science ®Google Scholar
• DeshantriAKKooijmansSAKuijpersSALiposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma modelJ Control Release201624324324927773734
   PubMed Web of Science ®Google Scholar
• RozemullerHvan der SpekEBogers-BoerLHA bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effectHaematologica20089371049105718492693
   PubMed Web of Science ®Google Scholar
• McmillinDWDelmoreJWeisbergETumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activityNat Med201016448348920228816
   PubMed Web of Science ®Google Scholar
• PoldervaartMTGremmelsHvan DeventerKProlonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architectureJ Control Release2014184586624727077
   PubMed Web of Science ®Google Scholar
• BrahamMVJAhlfeldTAkkineniAREndosteal and perivascular subniches in a 3D bone marrow model for multiple myelomaTissue Eng Part C Methods201824530031229652626
   PubMed Web of Science ®Google Scholar
• BelloniDHeltaiSPonzoniMModeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironmentHaematologica2018103470771629326121
   PubMed Web of Science ®Google Scholar
• GelainFBottaiDVescoviAZhangSDesigner self-assembling peptide nanofiber scaffolds for adult mouse neural stem cell 3-dimensional culturesPLoS One20061e11917205123
   PubMed Web of Science ®Google Scholar
• Ventura FerreiraMSBergmannCBodensiekIAn engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sitesJ Hematol Oncol20169426810307
   PubMed Web of Science ®Google Scholar
• PorterCJMoghimiSMIllumLDavisSSThe polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrowFEBS Lett1992305162661633861
   PubMed Web of Science ®Google Scholar
• DavisSSIliumLMoghimiSMMicrospheres for targeting drugs to specific body sitesJ Control Release1993241–3157163
   Web of Science ®Google Scholar
• LanghansSAThree-dimensional in vitro cell culture models in drug discovery and drug repositioningFront Pharmacol20189629410625
   PubMed Web of Science ®Google Scholar
• XuXFarach-CarsonMCJiaXThree-dimensional in vitro tumor models for cancer research and drug evaluationBiotechnol Adv20143271256126825116894
   PubMed Web of Science ®Google Scholar
• XuXSabanayagamCRHarringtonDAFarach-CarsonMCJiaXA hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeuticsBiomaterials201435103319333024447463
   PubMed Web of Science ®Google Scholar
• CharoenKMFallicaBColsonYLZamanMHGrinstaffMWEmbedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinationsBiomaterials20143572264227124360576
   PubMed Web of Science ®Google Scholar
• NgouneRPetersAvon ElverfeldtDWinklerKPützGAccumulating nanoparticles by EPR: a route of no returnJ Control Release2016238587027448444
   PubMed Web of Science ®Google Scholar
• SarinHPhysiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeabilityJ Angiogenes Res201021420701757
   PubMedGoogle Scholar
• OrlowskiRZVoorheesPMGarciaRAPhase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood200510583058306515626743
   PubMed Web of Science ®Google Scholar
• CiolliSLeoniFCasiniCBreschiCSantiniVBosiAThe addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myelomaBr J Haematol2008141681481918410447
   PubMed Web of Science ®Google Scholar
• AshleyJDStefanickJFSchroederVASuckowMAKiziltepeTBilgicerBLiposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivoJ Med Chem201457125282529224897555
   PubMed Web of Science ®Google Scholar
• MalamYLoizidouMSeifalianAMLiposomes and nanoparticles: nanosized vehicles for drug delivery in cancerTrends Pharmacol Sci2009301159259919837467
   PubMed Web of Science ®Google Scholar
• KiziltepeTAshleyJDStefanickJFRationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivoBlood Cancer J201224e6422829966
   PubMedGoogle Scholar
• StefanickJFAshleyJDBilgicerBEnhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker lengthACS Nano2013798115812724003770
   PubMed Web of Science ®Google Scholar
• AshleyJDStefanickJFSchroederVALiposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivoJ Control Release201419611312125312543
   PubMed Web of Science ®Google Scholar
• PatelAGKaufmannSHHow does doxorubicin work?Elife20121e0038723256047
   PubMed Web of Science ®Google Scholar
• TahoverEPatilYPGabizonAAEmerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomesAnticancer Drugs201526324125825415656
   PubMed Web of Science ®Google Scholar
• JaganathanHGageJLeonardFThree-dimensional in vitro co-culture model of breast tumor using magnetic levitationSci Rep20144646825270048
   PubMed Web of Science ®Google Scholar
• GoldeTEKooEHFelsensteinKMOsborneBAMieleLγ-Secretase inhibitors and modulatorsBiochim Biophys Acta20131828122898290723791707
   PubMed Web of Science ®Google Scholar
• PisklakovaAGrigsonEOzerovaMChenFSullivanDMNefedovaYAnti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironmentCancer Biol Ther201617547748526934342
   PubMed Web of Science ®Google Scholar
• BhavsarCMominMKhanTOmriATargeting tumor microenvironment to curb chemoresistance via novel drug delivery strategiesExpert Opin Drug Deliv201815764166329301448
   PubMed Web of Science ®Google Scholar
• MitsiadesCSDaviesFELaubachJPFuture directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myelomaJ Clin Oncol201129141916192321482978
   PubMed Web of Science ®Google Scholar